BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, Thirot-Bidault A, Sobhani I, Malka D, Lecomte T, Locher C, Bonnetain F, Laurent-Puig P. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 2013;109:3057-66. [PMID: 24196786 DOI: 10.1038/bjc.2013.677] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Pai RK, Pai RK. A Practical Approach to the Evaluation of Gastrointestinal Tract Carcinomas for Lynch Syndrome. American Journal of Surgical Pathology 2016;40:e17-34. [DOI: 10.1097/pas.0000000000000620] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
2 Alvi MA, McArt DG, Kelly P, Fuchs MA, Alderdice M, McCabe CM, Bingham V, McGready C, Tripathi S, Emmert-Streib F, Loughrey MB, McQuaid S, Maxwell P, Hamilton PW, Turkington R, James JA, Wilson RH, Salto-Tellez M. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget 2015;6:20863-74. [PMID: 26315110 DOI: 10.18632/oncotarget.4576] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
3 Buaisha H, Nippoldt E, Alsuwaidan AN, Reddymasu S. Small Bowel Adenocarcinoma in Celiac Disease: a Case Report. J Gastrointest Cancer 2018;49:333-6. [PMID: 27888391 DOI: 10.1007/s12029-016-9896-3] [Reference Citation Analysis]
4 Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, Kasper P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Buettner R, Merkelbach-Bruse S. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. BMC Gastroenterol 2019;19:21. [PMID: 30717682 DOI: 10.1186/s12876-019-0942-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Pelizzaro F, Marsilio I, Fassan M, Piazza F, Barberio B, D'Odorico A, Savarino EV, Farinati F, Zingone F. The Risk of Malignancies in Celiac Disease-A Literature Review. Cancers (Basel) 2021;13:5288. [PMID: 34771450 DOI: 10.3390/cancers13215288] [Reference Citation Analysis]
6 Cordova-Delgado M, Pizarro G, Pinto MP, Herrera ME, Garrido M. Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma. Front Oncol 2021;11:593561. [PMID: 33777741 DOI: 10.3389/fonc.2021.593561] [Reference Citation Analysis]
7 Pan H, Cheng H, Wang H, Ge W, Yuan M, Jiang S, Wan X, Dong Y, Liu Z, Zhao R, Fang Y, Lou F, Cao S, Han W. Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma. Cancer Sci 2021;112:4758-71. [PMID: 34449929 DOI: 10.1111/cas.15119] [Reference Citation Analysis]
8 Zhang H, Zhang X, Xu W, Wang J. TMC5 is Highly Expressed in Human Cancers and Corelates to Prognosis and Immune Cell Infiltration: A Comprehensive Bioinformatics Analysis. Front Mol Biosci 2022;8:810864. [DOI: 10.3389/fmolb.2021.810864] [Reference Citation Analysis]
9 Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol 2017;80:333-42. [PMID: 28653251 DOI: 10.1007/s00280-017-3371-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Vanoli A, Grillo F, Guerini C, Neri G, Arpa G, Klersy C, Nesi G, Giuffrida P, Sampietro G, Ardizzone S, Fociani P, Fiocca R, Latella G, Sessa F, D'Errico A, Malvi D, Mescoli C, Rugge M, Ferrero S, Poggioli G, Rizzello F, Macciomei MC, Santini D, Volta U, De Giorgio R, Caio G, Calabrò A, Ciacci C, D'Armiento M, Rizzo A, Solina G, Martino M, Tonelli F, Villanacci V, Cannizzaro R, Canzonieri V, Florena AM, Biancone L, Monteleone G, Caronna R, Ciardi A, Elli L, Caprioli F, Vecchi M, D'Incà R, Zingone F, D'Odorico A, Lenti MV, Oreggia B, Reggiani Bonetti L, Giannone AG, Orlandi A, Barresi V, Ciccocioppo R, Amodeo G, Biletta E, Luinetti O, Pedrazzoli P, Pietrabissa A, Corazza GR, Solcia E, Paulli M, Di Sabatino A. Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas. Ann Surg Oncol 2021;28:1167-77. [PMID: 32761330 DOI: 10.1245/s10434-020-08926-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Tessier-Cloutier B, Cai E, Schaeffer DF. Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagn Pathol 2019;14:62. [PMID: 31221175 DOI: 10.1186/s13000-019-0843-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TRJ. Small Bowel Adenocarcinoma. Gastroenterology Clinics of North America 2016;45:447-57. [DOI: 10.1016/j.gtc.2016.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
13 Khosla D, Dey T, Madan R, Gupta R, Goyal S, Kumar N, Kapoor R. Small bowel adenocarcinoma: An overview. World J Gastrointest Oncol 2022; 14(2): 413-422 [DOI: 10.4251/wjgo.v14.i2.413] [Reference Citation Analysis]
14 Legué LM, van Erning FN, Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. Target Oncol 2019;14:699-705. [PMID: 31625001 DOI: 10.1007/s11523-019-00681-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T, Deutsch D, Vernerey D, Puig PL. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort. Int J Cancer 2021;148:1731-42. [PMID: 33186471 DOI: 10.1002/ijc.33392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 2017;3:1546-53. [PMID: 28617917 DOI: 10.1001/jamaoncol.2017.1051] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 13.8] [Reference Citation Analysis]
17 Ishizu K, Hashimoto T, Naka T, Yatabe Y, Kojima M, Kuwata T, Nonaka S, Oda I, Esaki M, Kudo M, Gotohda N, Yoshida T, Yoshikawa T, Sekine S. APC mutations are common in adenomas but infrequent in adenocarcinomas of the non-ampullary duodenum. J Gastroenterol 2021;56:988-98. [PMID: 34514550 DOI: 10.1007/s00535-021-01823-x] [Reference Citation Analysis]
18 Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res 2019;25:641-51. [PMID: 30352910 DOI: 10.1158/1078-0432.CCR-18-1480] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sánchez A, Bujanda L, Cuatrecasas M, Bofill A, Alvarez-urturi C, Hernandez G, Aguilera L, Carballal S, Llach J, Herrera-pariente C, Iglesias M, Rivero-sánchez L, Jung G, Moreno L, Ocaña T, Bayarri C, Pellise M, Castells A, Castellví-bel S, Balaguer F, Moreira L. Identification of Lynch Syndrome Carriers among Patients with Small Bowel Adenocarcinoma. Cancers 2021;13:6378. [DOI: 10.3390/cancers13246378] [Reference Citation Analysis]
20 Braga VM, de Oliveira MB, Netto CC, Ibrahim RE, Peixoto RD. Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature. Case Rep Oncol 2015;8:285-9. [PMID: 26351435 DOI: 10.1159/000437257] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Fields AC, Lu PW, Li GZ, Welten V, Jolissaint JS, Vierra BM, Saadat LV, Larson AC, Atkinson RB, Melnitchouk N. Current practices and future steps for hyperthermic intraperitoneal chemotherapy. Curr Probl Surg 2020;57:100727. [PMID: 32151327 DOI: 10.1016/j.cpsurg.2019.100727] [Reference Citation Analysis]
22 Underhill ML, Germansky KA, Yurgelun MB. Advances in Hereditary Colorectal and Pancreatic Cancers. Clin Ther 2016;38:1600-21. [PMID: 27045993 DOI: 10.1016/j.clinthera.2016.03.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
23 Tesfay M, Xianzhong DD, Poddar N. Unusual case of primary adenocarcinoma of the small bowel and lung occurring in a patient: a case report and review of literature. J Gastrointest Cancer 2015;46:80-4. [PMID: 25544364 DOI: 10.1007/s12029-014-9677-9] [Reference Citation Analysis]
24 Mitsushita J, Netsu S, Suzuki K, Nokubi M, Tanaka A. Metastatic Ovarian Tumors Originating From a Small Bowel Adenocarcinoma - A Case Report and Brief Literature Review. Int J Gynecol Pathol 2017;36:253-60. [PMID: 27513076 DOI: 10.1097/PGP.0000000000000314] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Rovers KP, de Bree E, Yonemura Y, de Hingh IH. Treatment of peritoneal metastases from small bowel adenocarcinoma. International Journal of Hyperthermia 2017;33:571-8. [DOI: 10.1080/02656736.2016.1266700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
26 Zaaimi Y, Aparicio T, Laurent-Puig P, Taieb J, Zaanan A. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. Clin Res Hepatol Gastroenterol. 2016;40:154-160. [PMID: 26547136 DOI: 10.1016/j.clinre.2015.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
27 Vanoli A, Di Sabatino A, Martino M, Klersy C, Grillo F, Mescoli C, Nesi G, Volta U, Fornino D, Luinetti O, Fociani P, Villanacci V, D'Armiento FP, Cannizzaro R, Latella G, Ciacci C, Biancone L, Paulli M, Sessa F, Rugge M, Fiocca R, Corazza GR, Solcia E. Small bowel carcinomas in celiac or Crohn's disease: distinctive histophenotypic, molecular and histogenetic patterns. Mod Pathol 2017;30:1453-66. [PMID: 28664941 DOI: 10.1038/modpathol.2017.40] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
28 Liu Y, Yonemura Y, Levine EA, Glehen O, Goere D, Elias D, Morris DL, Sugarbaker PH, Tuech JJ, Cashin P, Spiliotis JD, de Hingh I, Ceelen W, Baumgartner JM, Piso P, Katayama K, Deraco M, Kusamura S, Pocard M, Quenet F, Fushita S; BIG-RENAPE Group. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Ann Surg Oncol 2018;25:1184-92. [PMID: 29484565 DOI: 10.1245/s10434-018-6369-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
29 Ito T, Ishida H, Suzuki O, Chika N, Amano K, Ishibashi K, Kamae N, Tada Y, Akagi K, Eguchi H, Okazaki Y. Prevalence and Molecular Characterization of Defective DNA Mismatch Repair in Small-bowel Carcinoma in a Japanese Hospital-based Population. J Anus Rectum Colon 2020;4:165-73. [PMID: 33134597 DOI: 10.23922/jarc.2020-026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Vergara JP, Sacdalan DBL, Amurao-amante M, Sacdalan DL. Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. Rare Tumors 2019;11:203636131882541. [DOI: 10.1177/2036361318825413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Pourmand K, Itzkowitz SH. Small Bowel Neoplasms and Polyps. Curr Gastroenterol Rep 2016;18:23. [PMID: 27086004 DOI: 10.1007/s11894-016-0497-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
32 Klose J, Lasitschka F, Horsch C, Strowitzki MJ, Bruckner T, Volz C, Schmidt T, Schneider M. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma. Scand J Gastroenterol 2020;55:321-9. [PMID: 32191146 DOI: 10.1080/00365521.2020.1734073] [Reference Citation Analysis]
33 Watari J, Mitani S, Ito C, Tozawa K, Tomita T, Oshima T, Fukui H, Kadowaki S, Natsume S, Senda Y, Tajika M, Hara K, Yatabe Y, Shimizu Y, Muro K, Morimoto T, Hirota S, Das KM, Miwa H. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Sci Rep 2019;9:10526. [PMID: 31324814 DOI: 10.1038/s41598-019-46167-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology 2019;156:890-903. [PMID: 30578781 DOI: 10.1053/j.gastro.2018.11.071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
35 Fallah J, Afari ME, Cordova AC, Olszewski AJ, Minami T. Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. Case Rep Oncol Med 2015;2015:865383. [PMID: 26290763 DOI: 10.1155/2015/865383] [Reference Citation Analysis]
36 Yuan W, Zhang Z, Dai B, Wei Q, Liu J, Liu Y, Liu Y, He L, Zhou D. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations: Exome Sequencing of Duodenal Cancer. Cancer 2016;122:1689-96. [DOI: 10.1002/cncr.29974] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
37 Giuffrida P, Vanoli A, Arpa G, Bonometti A, Luinetti O, Solcia E, Corazza GR, Paulli M, Di Sabatino A. Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current Knowledge. Cancers (Basel) 2018;11:E31. [PMID: 30597986 DOI: 10.3390/cancers11010031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
38 Dave A, Wiseman JT, Cloyd JM. Duodenal adenocarcinoma: neoadjuvant and adjuvant therapy strategies. Expert Opinion on Orphan Drugs 2019;7:463-72. [DOI: 10.1080/21678707.2019.1684257] [Reference Citation Analysis]
39 Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, Jain V, Trivedi S, Stanway S, Cunningham D. Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer. 2015;15:15. [PMID: 25603878 DOI: 10.1186/s12885-015-1014-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
40 Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors. Cancers (Basel) 2021;13:467. [PMID: 33530449 DOI: 10.3390/cancers13030467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Jun S, Kim M, Jin Gu M, Kyung Bae Y, Chang H, Sun Jung E, Jang K, Kim J, Yu E, Woon Eom D, Hong S. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. Mod Pathol 2016;29:402-15. [DOI: 10.1038/modpathol.2016.40] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
42 Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P; NADEGE Investigators. Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. Int J Cancer 2020;147:967-77. [PMID: 31912484 DOI: 10.1002/ijc.32860] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
43 Xue Y, Balci S, Aydin Mericoz C, Taskin OC, Jiang H, Pehlivanoglu B, Muraki T, Memis B, Saka B, Kim GE, Bandopadhyay S, Knight J, El-Rayes BF, Sarmiento J, Reid MD, Erkan M, Basturk O, Adsay V. Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. Cancer 2020;126:4788-99. [PMID: 32857459 DOI: 10.1002/cncr.33135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yoshida M, Yabuuchi Y, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M; Japan Duodenal Cancer Guideline Committee. The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry. J Gastroenterol Hepatol 2021;36:1216-21. [PMID: 33002211 DOI: 10.1111/jgh.15285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Suzuki H, Hirata Y, Suzuki N, Ihara S, Sakitani K, Kobayashi Y, Kinoshita H, Hayakawa Y, Yamada A, Watabe H, Tateishi K, Ikenoue T, Yamaji Y, Koike K. Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma. Am J Pathol 2015;185:550-62. [PMID: 25478808 DOI: 10.1016/j.ajpath.2014.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
46 Zhang Y, Zulfiqar M, Bluth MH, Bhalla A, Beydoun R. Molecular Diagnostics in the Neoplasms of Small Intestine and Appendix. Clinics in Laboratory Medicine 2018;38:343-55. [DOI: 10.1016/j.cll.2018.03.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
47 Xia M, Singhi AD, Dudley B, Brand R, Nikiforova M, Pai RK. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome–associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency. Applied Immunohistochemistry & Molecular Morphology 2017;25:399-406. [DOI: 10.1097/pai.0000000000000389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Rosenbaum MW, Gonzalez RS. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. Semin Diagn Pathol 2021:S0740-2570(21)00078-2. [PMID: 34740486 DOI: 10.1053/j.semdp.2021.10.003] [Reference Citation Analysis]
49 Lech G, Korcz W, Kowalczyk E, Słotwiński R, Słodkowski M. Primary small bowel adenocarcinoma: current view on clinical features, risk and prognostic factors, treatment and outcome. Scand J Gastroenterol 2017;52:1194-202. [PMID: 28737049 DOI: 10.1080/00365521.2017.1356932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
50 Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer. 2014;50:1740-1746. [PMID: 24797764 DOI: 10.1016/j.ejca.2014.04.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
51 Sacdalan DB, Mendoza MJ, Vergara JP, Catedral LI, Ting FI, Leones LM, Berba CM, Sacdalan DL. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma. Med Oncol 2020;37:106. [PMID: 33135102 DOI: 10.1007/s12032-020-01432-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Chen EY, Vaccaro GM. Small Bowel Adenocarcinoma. Clin Colon Rectal Surg 2018;31:267-77. [PMID: 30186048 DOI: 10.1055/s-0038-1660482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
53 McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, Horvath LE, Schneider DJ, Hobday TJ, Jatoi A, Meyers JP, Goetz MP. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 2017;123:3494-501. [PMID: 28493308 DOI: 10.1002/cncr.30766] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
54 Hirao M, Komori M, Nishida T, Iijima H, Yamaguchi S, Ishihara R, Yasunaga Y, Kobayashi I, Kishida O, Oshita M, Hagiwara H, Ito T, Suzuki K, Hayashi Y, Inoue T, Tsujii M, Yoshihara H, Takehara T. Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum. Oncol Lett 2017;14:1628-36. [PMID: 28789389 DOI: 10.3892/ol.2017.6290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M, Nakagawa M, Hori S, Inoue M, Inaba T, Imagawa A, Takatani M, Takenaka R, Suzuki S, Fujiwara T, Okada H. The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer. 2017;117:1607-1613. [PMID: 28982111 DOI: 10.1038/bjc.2017.338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
56 González I, Goyal B, Xia MD, Pai RK, Ma C. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. Human Pathology 2019;85:18-26. [DOI: 10.1016/j.humpath.2018.10.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
57 Wu S, Chen JN, Zhang QW, Tang CT, Zhang XT, Tang MY, Li XB, Ge ZZ. A New Metastatic Lymph Node Classification-based Survival Predicting Model in Patients With Small Bowel Adenocarcinoma: A Derivation and Validation Study. EBioMedicine 2018;32:134-41. [PMID: 29908920 DOI: 10.1016/j.ebiom.2018.05.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
58 Azizi AH, Inam ZS, Farrell TJ. Patient with Lynch syndrome with subsequent development of small bowel adenocarcinoma. BMJ Case Rep 2018;2018:bcr-2018-225003. [PMID: 29866690 DOI: 10.1136/bcr-2018-225003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 de Bree E, Rovers KP, Stamatiou D, Souglakos J, Michelakis D, de Hingh IH. The evolving management of small bowel adenocarcinoma. Acta Oncologica 2018;57:712-22. [DOI: 10.1080/0284186x.2018.1433321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
60 Gallon R, Gawthorpe P, Phelps RL, Hayes C, Borthwick GM, Santibanez-Koref M, Jackson MS, Burn J. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies. Cancers (Basel) 2021;13:406. [PMID: 33499123 DOI: 10.3390/cancers13030406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
61 Safyan RA, Neugut AI. Anti-EGFR Therapy in Small Bowel Adenocarcinoma. Oncologist 2018;23:275-6. [PMID: 29438094 DOI: 10.1634/theoncologist.2017-0688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Amano T, Iijima H, Shinzaki S, Tashiro T, Iwatani S, Tani M, Otake Y, Yoshihara T, Sugimoto A, Egawa S, Yamaguchi S, Kinoshita K, Araki M, Hirao M, Sakakibara Y, Hiyama S, Ogawa H, Nagaike K, Murata J, Komori M, Okuda Y, Kizu T, Tsujii Y, Hayashi Y, Inoue T, Takahashi H, Mizushima T, Morii E, Takehara T. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma. BMC Cancer 2021;21:978. [PMID: 34465291 DOI: 10.1186/s12885-021-08724-5] [Reference Citation Analysis]